N-Substituted pyrimidinethione and acetophenone derivatives as a new therapeutic approach in diabetes

dc.contributor.authorTaslimi, Parham
dc.contributor.authorSujayev, Afsun
dc.contributor.authorKaraman, Muhammet
dc.contributor.authorMaharramova, Gunel
dc.contributor.authorSadeghian, Nastaran
dc.contributor.authorOsmanova, Sabiya
dc.contributor.authorSardarova, Sabira
dc.contributor.authorSadeghian, Nastaran
dc.contributor.authorTaslimi, Parham
dc.date.accessioned2025-10-18T13:23:11Z
dc.date.created2020
dc.date.issued2020
dc.departmentFakülteler, Fen Fakültesi, Biyoteknoloji Bölümü
dc.departmentFakülteler, Mühendislik Mimarlık ve Tasarım Fakültesi, Çevre Mühendisliği Bölümü
dc.description.abstractIn this study, compounds with 4-hydroxybutyl, 4-phenyl, 5-carboxylate, and pyrimidine moieties were determined as alpha-glycosidase inhibitors.N-Substituted pyrimidinethione and acetophenone derivatives (A1-A5,B1-B11, andC1-C11) were good inhibitors of the alpha-glycosidase enzyme, withK(i)values in the range of 104.27 +/- 15.75 to 1,004.25 +/- 100.43 nM. Among them, compoundB7was recorded as the best inhibitor, with aK(i)of 104.27 +/- 15.75 nM against alpha-glycosidase. In silico studies were carried out to clarify the binding affinity and interaction mode of the compounds with the best inhibition score against alpha-glycosidase fromSaccharomyces cerevisiae. CompoundsB7(S) andB11(R) exhibited a good binding affinity with docking scores of -8.608 and 8.582 kcal/mol, respectively. The docking results also showed that the 4-hydroxybutyl and pyrimidinethione moieties play a key role inS. cerevisiaeand human alpha-glycosidase inhibition.
dc.identifier.doi10.1002/ardp.202000075
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue9
dc.identifier.orcidSadeghian, nastaran/0009-0004-2966-9231
dc.identifier.orcidSucayev, Afsun/0000-0002-4135-9568
dc.identifier.orcidGulcin, ilhami/0000-0001-5993-1668
dc.identifier.orcidOsmanova, Sabiya/0000-0003-4438-4117
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidKaraman, Muhammet/0000-0002-0155-3390
dc.identifier.orcidUCUN OZEL, HANDAN/0000-0003-1293-0945
dc.identifier.pmid32537841
dc.identifier.scopus2-s2.0-85090077438
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/ardp.202000075
dc.identifier.urihttps://hdl.handle.net/11772/22729
dc.identifier.volume353
dc.identifier.wosWOS:000567558100003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subjectAcetophenone
dc.subjectDiabetes Mellitus
dc.subjectMolecular Docking
dc.subjectN-Substituted Pyrimidinethione
dc.subjectAlpha-Glycosidase
dc.titleN-Substituted pyrimidinethione and acetophenone derivatives as a new therapeutic approach in diabetes
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication7f83844e-1b57-4c97-b59d-6bd6facb1def
relation.isAuthorOfPublicationdadfa319-65b8-4543-92b4-bea49e0139e9
relation.isAuthorOfPublication.latestForDiscovery7f83844e-1b57-4c97-b59d-6bd6facb1def

Dosyalar